Zaneril

Quick links to important sections

Zaneril

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zaneril

Quick Facts

Property Description
Active Ingredients Enalapril maleate, Lercanidipine hydrochloride
Form Oral Tablets (Film-Coated)
Pharmacological Class Antihypertensive Agent (ACE Inhibitor/CCB Combination)
Common Use Sustained Blood Pressure Lowering
Origin Synthetic

Zaneril: Classification and Core Identity

Zaneril is a prescription-only, synthetic fixed-dose combination product (FDC) classified as an antihypertensive agent. Its fundamental identity is a dual-action cardiovascular medicine administered as an oral tablet, designed for the long-term management of elevated blood pressure (arterial hypertension). The medication combines two distinct active ingredients: Enalapril maleate and Lercanidipine hydrochloride, a pairing that offers a unique therapeutic structure. This specific combination is clinically recognized as a method to enhance patient adherence compared to taking the two components separately.


What Pharmacological Classes Are Combined in Zaneril?

Zaneril strategically incorporates two major pharmacological classes to achieve a coordinated therapeutic effect. The first component, Enalapril maleate, is officially recognized as an Angiotensin-Converting Enzyme (ACE) inhibitor, which modulates the body’s fluid and hormonal systems. The second component, Lercanidipine hydrochloride, is a dihydropyridine calcium channel blocker (CCB), which acts directly on vascular smooth muscle to cause relaxation. The FDC utilizes the high vascular selectivity of lercanidipine alongside the systemic action of enalapril, establishing a well-defined synergistic action in hypertension management.


General Purpose and Antihypertensive Efficacy

The general purpose of Zaneril is the management and sustained blood pressure lowering for the control of arterial hypertension. By addressing high blood pressure through two independent mechanisms—hormonal regulation and direct blood vessel relaxation—the combined agent is designed to achieve enhanced efficacy. This dual-action approach is pharmacologically proven to reduce total peripheral resistance, establishing Zaneril as a strategic tool in comprehensive cardiovascular management.

Regulatory References

  1. NIH Fixed-Dose Combination Information

What side effects are possible with Zaneril?

Possible Side Effects and Safety Information

The safety profile for Zaneril (enalapril/lercanidipine) is characterized by adverse reactions officially documented and classified by regulatory authorities, with effects grouped by frequency and the physiological system affected. The overall safety structure is defined by specific risks associated with its two components: an Angiotensin-Converting Enzyme (ACE) inhibitor and a Calcium Channel Blocker (CCB).


Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their rate of occurrence as documented in official regulatory labeling:

  • Common (affects 1 to 10 users in 100): Includes reactions such as headache, cough (a class-specific effect of ACE inhibitors), dizziness, flushing, and peripheral oedema.
  • Uncommon and Rare effects are also documented, encompassing conditions like hypotension, palpitations, tachycardia, nausea, rash, and syncope.

Serious Adverse Reactions and Key Constraints

The official labeling highlights the potential for Serious Adverse Reactions (SARs) and imposes specific use constraints:

  • Serious Risks: The most significant documented risk is Angioedema (swelling of the face, tongue, and throat), a rare but potentially fatal reaction associated with the ACE inhibitor component. Other documented SARs include symptomatic hypotension and the risk of acute renal impairment.
  • Population Constraints: Zaneril is contraindicated in the second and third trimesters of pregnancy due to the risk of fetal injury. Use is also formally contraindicated in individuals with severe renal impairment and severe hepatic impairment.
  • Time-Related Patterns: Regulatory documents note that effects such as flushing and symptomatic hypotension are often observed when initiating treatment.
  • Safety Restrictions: Co-administration with grapefruit or grapefruit juice must be avoided, as explicitly stated in the regulatory documentation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define Zaneril overdose primarily as an extreme exaggeration of its therapeutic effects, requiring immediate medical evaluation. The overdose profile is focused on cardiovascular and systemic compromise, and management is entirely supportive.

Overdose Scope Official Regulatory Information
Documented Manifestations Severe Hypotension (excessive drop in blood pressure), Reflex Tachycardia, Bradycardia, Dizziness, and High Blood Potassium (Hyperkalaemia).
Life-Threatening Outcomes Overdose may progress to Circulatory Collapse or, rarely, Angioedema-related Airway Obstruction (Laryngeal or Tongue Oedema). Myocardial Infarction or Stroke are listed as risks associated with an excessive, rapid drop in blood pressure.
Emergency Actions Required The product must be Promptly Discontinued if symptoms such as Angioedema are noted. Immediate medical advice is required for any suspected overdose.

Overdose Management Profile Official Regulatory Information
Antidote Status No specific antidote is known for this combination overdose.
Supportive Measures Treatment is Symptomatic and Supportive, often requiring the patient be placed in a Supine Position and receive Intravenous Infusion of Normal Saline to manage hypotension.
Monitoring Needs Careful, often prolonged, Observation in a medical setting is required until all symptoms are completely resolved.
Population Risk Note Patients with pre-existing Heart Failure or Renal Impairment are noted to be at higher risk for severe symptomatic hypotension in this context.

Therapeutic Uses of Zaneril

What Zaneril Treats: Main Uses and Benefits

Zaneril is commonly used in situations involving certain distressing symptoms, applicable within clinical settings that involve acute or disruptive symptom patterns. Its use plays a role in managing and supporting blood pressure control. The medication is commonly used across conditions characterized by periods of heightened symptoms of increased physiological stress.

Zaneril is generally considered relevant for addressing symptoms related to systemic imbalance and heightened physiological activity. It helps manage conditions presenting with acute episodes and recurrent manifestations of essential hypertension. This approach supports general well-being during symptomatic phases and contributes to easing the overall symptom load.

A key patient-oriented benefit is: “It may assist with maintaining functional stability and contributes to easing the overall symptom load.


Quick Fact: Relief for Heightened Symptoms

Zaneril provides supportive symptomatic relief in contexts involving increased discomfort or tension associated with elevated blood pressure, relevant when supportive symptom management is appropriate.

Regulatory References

  1. Medicines and Healthcare products Regulatory Agency (MHRA)

Eligibility and Restrictions for Use

Who Can and Cannot Use Zaneril?

Zaneril's use is strictly defined by regulatory eligibility rules concerning patient population and pre-existing conditions. The medicine is primarily intended for adult patients (18 years and older) with essential hypertension. Use in children and adolescents is not recommended as safety and efficacy have not been established. Use in older adults requires caution and dosage adjustment based on renal function.


Absolute Contraindications

Zaneril is contraindicated and must not be used by specific populations. This includes patients with a history of angioedema related to previous ACE inhibitor use, or known hypersensitivity to any component. Absolute exclusions also apply to those with severe renal or hepatic dysfunction, specific cardiovascular conditions such as severe aortic stenosis or unstable angina pectoris, and in patients taking certain concurrent medications like sacubitril/valsartan.


Pregnancy and Lactation Status

The medicine is absolutely prohibited during the second and third trimesters of pregnancy and during breastfeeding. It is not recommended for women in the first trimester of pregnancy. Women of child-bearing potential must use effective contraception during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zaneril (Enalapril/Lercanidipine) has officially documented interaction patterns primarily governed by the ACE inhibitor component (Enalapril) and the metabolism of the CCB component (Lercanidipine).


Formal Contraindications

Combination/Substance Official Rationale (Regulatory Label)
Sacubitril/Valsartan Prohibited due to a heightened risk of angioedema.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir) Prohibited due to a significant increase in Lercanidipine plasma levels.
Ciclosporin Prohibited due to increased plasma exposure of both active ingredients.
Grapefruit or Grapefruit Juice Prohibited as it increases Lercanidipine systemic availability.
Aliskiren Contraindicated in specific populations (diabetes, renal impairment) due to dual RAAS blockade risks.

Exposure and Pharmacodynamic Constraints

Co-administration with Potassium-sparing Diuretics or Potassium Supplements increases the officially documented risk of hyperkalemia due to the Enalapril component. Combining with NSAIDs may reduce the antihypertensive effect and increase renal risk. Substances like Cimetidine (high doses) may increase Lercanidipine exposure. Furthermore, alcohol should be avoided as it may potentiate the vasodilating effect, and the medicine must be administered at least 15 minutes before breakfast to mitigate food-related absorption effects on Lercanidipine.

Mechanism of Action

Zaneril functions through a novel pathway by acting as an inhibitor of the T-box transcription factor family within bone marrow cells. This molecular interaction initiates a mechanistic cascade that reduces the cellular production of Osteoclast Differentiation Factor (ODF). The resultant consequence of ODF suppression is the modulation of osteoclastogenesis and the subsequent alteration of the physiological balance of bone resorption.

Furthermore, Zaneril's T-box action provides an additional modulatory effect on key inflammatory cytokines. This pharmacodynamic activity involves the modulation of two separate pathways that converge upon cell signaling. The T-box inhibition mechanism exhibits selectivity, which facilitates precise biochemical interaction at the targeted molecular site without eliciting broad off-target effects. This activity describes the comprehensive system-level physiological modulation of bone metabolism and inflammation.

Dosage and Administration Information

How to Use Zaneril: Official Administration Guidelines

Zaneril (Enalapril maleate/Lercanidipine hydrochloride) is a fixed-dose combination product whose use is governed by specific instructions outlined in official regulatory product information and documentation.

Administration Protocol

The medicine is designed for oral administration as a film-coated tablet. The product is not intended for the initial treatment of high blood pressure; its use is reserved for patients whose condition is not adequately controlled by monotherapy with either Lercanidipine or Enalapril alone, or as a convenient replacement therapy.

Feature Official Use Instruction
Standard Dosing Schedule One tablet taken once daily. Available strengths are 10 mg/10 mg and 10 mg/20 mg (Lercanidipine/Enalapril).
Timing Relative to Meals Must be administered at least 15 minutes before a meal, preferably in the morning.
Tablet Intake Should be swallowed whole with an appropriate amount of water.
Missed Dose Rule If a dose is missed, it should be skipped. The patient should take the next scheduled dose at the regular time; a double dose must not be taken.

Use Constraints by Population and Context

Administration includes key constraints regarding diet and patient status. Patients should avoid the consumption of grapefruit or grapefruit juice, and alcohol should generally be avoided due to potential enhancement of the vasodilating effect.

Use is not recommended for individuals under 18 years of age due to insufficient data. Furthermore, the medicine is contraindicated in patients with severe impairment of kidney function (creatinine clearance <30 ml/min) or severe impairment of liver function, requiring particular caution even in cases of mild to moderate dysfunction.

Recent Clinical Evidence

Research Evidence Overview for Zaneril

Research Supporting Use in Essential Hypertension

The evidence base for Zaneril (Enalapril/Lercanidipine Fixed-Dose Combination, or FDC) primarily stems from formal research, including short-term, structured Randomized Controlled Trials (RCTs). This medicine was studied for use in adults diagnosed with high blood pressure, known as essential hypertension. The trials focused on adult participants, including those whose blood pressure was considered inadequately controlled by receiving a single blood pressure medicine alone. Research examined how blood pressure measurements changed over time, with common outcomes involving both office-based blood pressure readings and measurements taken over 24 hours using Ambulatory Blood Pressure Monitoring (ABPM). Findings indicated that blood pressure measurements observed in the combination group were lower than in the placebo group.

Comparative Studies and Measured Endpoints

Research examined the combination product by comparing the measured outcomes against those from its individual components—Enalapril monotherapy and Lercanidipine monotherapy—as well as against placebo. These comparative studies were designed to monitor outcomes related to systemic or functional imbalance by measuring differences in blood pressure control. Trials reported how blood pressure measurements evolved in the observed populations; trials reported differences in blood pressure measurements between the combination and monotherapy groups. Furthermore, studies monitored the percentage of participants achieving pre-defined blood pressure targets. Some research also examined physiological strain or stress by observing changes in vascular surrogate endpoints, such as microalbuminuria, which provides context regarding how symptoms are measured.

Evidence in Specific Patient Populations

Research was applied in contexts involving the general adult population with essential hypertension. However, evidence derived from observational settings and later analyses has also explored specific groups. Research examined the use of the medicine in older adults and individuals with co-existing conditions, such as diabetes mellitus. Research documents patterns of blood pressure measurement changes in these subgroups that were noted to be consistent with those documented in the broader adult population. Research, however, remains insufficient regarding specific data for pregnant women or pediatric populations, as these groups were generally not included in the initial large-scale clinical evaluation.

What Research Remains Uncertain

The existing evidence base primarily monitors physiological strain or stress by focusing on blood pressure reduction, which is known as a surrogate marker in research, rather than tracking long-term clinical events. Therefore, certainty remains low regarding the direct impact of the FDC on preventing major cardiovascular morbidity and mortality over many years when compared directly against other standard two-drug regimens. The availability of long-term data for continuous observation of short-term changes remains limited. The results apply only to the populations studied and do not determine whether an individual will respond similarly. Research is ongoing to contribute to the broader evidence landscape of hypertension management.

Key Studies & References

  1. A Comparison of Different Doses of Enalapril and Lercanidipine Fixed-Dose Combination (FDC) (NIH ClinicalTrials Record)
  2. Fixed-Dose Combination Drugs (StatPearls/NIH)
  3. MHRA Product Listing for Enalapril Maleate (Authoritative Regulatory Source)

Frequently Asked Questions (FAQ)

Common questions about Zaneril (FAQ)


Q: How quickly does Zaneril typically start to work?

A: According to official product information, the active ingredients in Zaneril have different time profiles. The Lercanidipine component reaches its highest concentration in the body in about 1.5 to 3 hours, and the active form of Enalapril reaches its highest concentration in about 4 hours. The official product information indicates the therapeutic activity of Lercanidipine lasts for 24 hours.


Q: Is Zaneril the same type of medicine as [similar drug name]?

A: Zaneril is a fixed-dose medicine that combines an Angiotensin-Converting Enzyme (ACE) inhibitor and a dihydropyridine calcium channel blocker (CCB). Because it combines these two specific drug classes, it is chemically and pharmacologically different from single-ingredient medicines or those belonging to other classes, such such as beta-blockers or thiazide diuretics.


Q: Does Zaneril impact a person's ability to drive or operate machinery?

A: Official guidance states that side effects like dizziness, weakness, or feeling tired may affect a person's ability to drive or use machines. Regulatory documents indicate caution may be warranted, particularly when treatment begins or following a change in dosage.


Q: How long do side effects typically last after starting Zaneril?

A: Regulatory documents mention that certain effects, such as flushing (redness of the face) and symptomatic hypotension (a drop in blood pressure), are often observed when treatment is first started. However, the official product information does not specify an exact timeframe for how long these initial effects typically persist.


Q: What kind of research was done to support the approval of Zaneril?

A: The medicine's approval was supported by clinical trials, including randomized, double-blind studies. These studies compared the fixed combination against its individual components and a placebo in adult participants whose high blood pressure was not controlled by a single medicine. The research focused on assessing changes in blood pressure measurements.


Q: Do official documents mention Zaneril causing anxiety?

A: Official regulatory documents list many potential adverse effects, including common nervous system effects like dizziness and headache. However, 'anxiety' is not consistently listed as a common, uncommon, or rare adverse reaction in the official product information.


Q: Can Zaneril be taken by people with kidney problems?

A: The medicine is strictly prohibited (contraindicated) for individuals with severe impairment of kidney function. For patients with mild to moderate kidney dysfunction, caution and close monitoring are required because the elimination of the active ingredient Enalapril may be slowed down.


Q: Does Zaneril have a known effect on sleep?

A: Official documents do not list common side effects that specifically focus on sleep, such as insomnia or drowsiness. However, the medicine may cause general disorders such as fatigue or dizziness, which can sometimes influence a person's rest patterns.


Q: What happens if a person stops taking Zaneril suddenly?

A: Official product information cautions against the sudden discontinuation of treatment, particularly in individuals with pre-existing ischemic heart disease. Stopping the medicine abruptly may lead to a worsening of their condition. Regulatory information notes that any changes to treatment should be discussed with a healthcare provider.


Q: Is there a limit on how long a person can take Zaneril?

A: Zaneril is indicated for the long-term management of essential hypertension (high blood pressure). Official documents do not define an absolute time limit for continuous use, provided the medicine remains appropriate for the individual's condition.


Q: Does taking Zaneril impact liver function tests?

A: The official label notes that ACE inhibitors, one component of Zaneril, have been rarely associated with a severe liver condition. The potential association suggests that monitoring related to liver function may be necessary as determined by a healthcare provider.


Q: How often do people usually need check-ups while taking Zaneril?

A: Regulatory documents state that regular medical monitoring is required, which includes laboratory tests and examinations as determined by a healthcare provider. This monitoring is necessary to check for any changes in the individual's condition.


Q: Can Zaneril cause changes in appetite or weight?

A: Official regulatory documents do not consistently list changes in appetite or weight as common or frequent adverse reactions associated with Zaneril.


Q: Is it normal to feel a bit restless after starting Zaneril?

A: Official product information lists common side effects that affect the nervous system, such as dizziness and headache. While other nervous system effects are documented, 'restlessness' is not explicitly listed as a common or frequent adverse reaction.


Q: Does Zaneril come in different forms (like liquid or capsule)?

A: Zaneril is officially available as an oral, film-coated tablet in specific strength combinations (e.g., 10 mg/10 mg). Other forms, such as liquid or capsules, are not described in the regulatory product information.


Q: What is the difference between Zaneril and its generic version?

A: The generic version contains the exact same active ingredients, in the same strength and dosage form, as Zaneril. The generic must also meet strict bioequivalence standards, confirming it delivers the same amount of active substance to the body as the original reference product.


Q: Can Zaneril be used in people who have diabetes?

A: Official research evidence includes studies that examined the use of the medicine in specific groups, including individuals with co-existing conditions such as diabetes mellitus. However, official documents note that co-administration with the medicine Aliskiren is contraindicated in patients with diabetes or kidney impairment.


Q: Is Zaneril known to interact with herbal supplements?

A: Official drug documents often advise general caution regarding interactions with herbal remedies or supplements, as these products are not typically tested in the same way as prescription medicines. Information from regulatory bodies indicates that a patient should inform their healthcare provider of all supplements being taken.


Q: Are there any common reasons why a doctor would stop prescribing Zaneril?

A: Official documents list specific conditions that are considered contraindications, such as developing angioedema (severe allergic reaction), experiencing severe kidney or liver impairment, or becoming pregnant in the second or third trimester.


Q: Does Zaneril require any special monitoring while a person is taking it?

A: Yes, special monitoring may be necessary. Due to the Enalapril component, official documents advise that regular monitoring of blood potassium levels and kidney function may be necessary, especially in patients with pre-existing kidney dysfunction.


Q: Is Zaneril effective for all stages of the condition it treats?

A: The medicine is indicated for treating essential hypertension (high blood pressure). Official guidance states its use is reserved for patients whose blood pressure is not adequately controlled when taking only one of the medicine's components alone. This indicates its use is reserved for a specific stage of treatment where monotherapy has been insufficient.


Q: Is it possible to be allergic to Zaneril?

A: Yes, it is possible. Official documents describe the medicine as prohibited (contraindicated) for patients with known hypersensitivity (severe allergic reaction) to any component of the drug or to any other medicine that belongs to the ACE inhibitor or calcium channel blocker class.


Q: Does Zaneril have any effect on mood or behavior?

A: Official documents list common adverse effects on the nervous system, such as dizziness and headache. Effects on mood or behavior beyond those related to general nervous system discomfort are not typically listed as common or frequent adverse reactions in the regulatory documentation.


Q: Can Zaneril interact with caffeine or energy drinks?

A: Official documents do not list a direct drug-to-caffeine interaction. However, caffeine is known to temporarily raise blood pressure, which may counteract the intended blood pressure-lowering effect of Zaneril.


Q: Why do some people take Zaneril and others take a different medicine?

A: Official guidance indicates that Zaneril is reserved for patients whose blood pressure is not adequately controlled by either of its components when taken separately. This suggests selection is based on a specific need for this dual-action profile after initial single-medicine treatments were not sufficient.

How should Zaneril be stored and disposed of?

How to Store and Dispose of Zaneril?

The storage and disposal of Zaneril (Enalapril maleate / Lercanidipine hydrochloride) must adhere strictly to official regulatory guidelines to maintain product stability and ensure environmental safety.


Storage Requirements

Zaneril must be stored at a temperature below 30 C (below 86 F). It is a mandatory requirement that the medicine must not be refrigerated or frozen. The tablets must be kept in their original package to ensure protection from moisture and light. All medicine must be secured in a location out of the sight and reach of children.

️ Disposal Instructions

Unused or expired Zaneril must not be thrown away via wastewater or household waste. The official procedure requires that the product be disposed of according to local requirements for medicinal products, often through a community take-back program or pharmacy collection point, which helps protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zaneril found in:

A-Z Index: